Lilly Still Trying to Buoy Investor Interest With AD Drug
I continue to see a curious, steady stream of news articles and blog posts about solanezumab, Lilly’s anti-amyloid MAb that performed only marginally in late-phase studies of Alzheimer disease (AD). This despite the fact that there’s little, if any, substance to report on the drug. Here’s just one recent example that attempts to keep solanezumab and Lilly top of mind and relevant. All I can say is that it’s apparently the result of Lilly’s ongoing PR investment to buoy shareholder interest in a company of dying interests. I’m certainly not experiencing any schadenfreude here (God knows, we need a disease-modifying compound in AD); but this kind of persistent commercial disregard for the painfully obvious is off-putting, to say the least.
A native East Tennessean, Barbara Martin is a formerly practicing, board-certified neurologist who received her BS (psychology, summa cum laude) and MD from Duke University before completing her postgraduate training (internship, residency, fellowship) at the Hospital of the University of Pennsylvania in Philadelphia. She has worked in academia, private practice, medical publishing, drug market research, and continuing medical education (CME). For the last 3 years, she has worked in a freelance capacity as a medical writer, analyst, and consultant. Follow Dr. Barbara Martin on Google + and Twitter.
